Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion (RaScaL)

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Ivan J. Suner, MD, Retina Associates of Florida, P.A.

ClinicalTrials.gov Identifier:

NCT00815360

First received: December 26, 2008

Last updated: February 4, 2015

Last verified: October 2014

History of Changes

Results First Received: May 23, 2013

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment
Condition:	Diabetic Macular Edema
Interventions:	Drug: intravitreal injection of ranibizumab Procedure: peripheral laser Drug: intravitreal injection of triamcinolone acetonide Procedure: macular laser

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
We included 30 treatment-naïve eyes of 22 patients (8 bilateral patients) aged ≥ 18 years of age, with Type 1 or 2 diabetes mellitus and visual impairment secondary to diabetic macular edema associated with peripheral nonperfusion on Ultra Widefield Fluorescein Angiography (UWFA).

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Treatment naive patients

Reporting Groups

	Description
Treatment Group 1	ranibizumab and scatter laser
Comparative Group 1	Intravitreal triamcinolone with macular laser

Participant Flow: Overall Study

	Treatment Group 1	Comparative Group 1
STARTED	11	11
COMPLETED	11	11
NOT COMPLETED	0	0

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Treatment Group 1	ranibizumab and scatter laser
Comparative Group 1	Intravitreal triamcinolone with macular laser
Total	Total of all reporting groups

Baseline Measures

	Treatment Group 1	Comparative Group 1	Total
Overall Participants Analyzed [Units: Participants]	11	11	22

Age [Units: Participants]
<=18 years	0	0	0
Between 18 and 65 years	10	11	21
>=65 years	1	0	1

Age [Units: Years] Mean (Standard Deviation)	57.7 (7.5)	58.3 (6.5)	58.0 (7.4)

Gender [Units: Participants]
Female	5	5	10
Male	6	6	12

Region of Enrollment [Units: Participants]
United States	11	11	22

Outcome Measures

Show All Outcome Measures

1. Primary:

Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters From Baseline to Month 6. [ Time Frame: 6 months ]

Show Outcome Measure 1

2. Secondary:

Mean Central Foveal Thickness (CFT) on Optical Coherence Tomography (OCT) in Microns at 6 Months [ Time Frame: 6 months ]

Show Outcome Measure 2

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
small study size

More Information

Hide More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:

Name/Title: Dr. Ivan J. Suner
Organization: Retina Associates of Florida, P.A.
phone: 813-875-6373
e-mail: ivansuner@gmail.com

Responsible Party:	Ivan J. Suner, MD, Retina Associates of Florida, P.A.
ClinicalTrials.gov Identifier:	NCT00815360 History of Changes
Other Study ID Numbers:	Pro00002813
Study First Received:	December 26, 2008
Results First Received:	May 23, 2013
Last Updated:	February 4, 2015

To Top